Publication | Open Access
Indoximod-based chemo-immunotherapy for pediatric brain tumors: A first-in-children phase I trial
34
Citations
30
References
2023
Year
Indoximod was well tolerated and could be safely combined with chemotherapy and radiation. Encouraging preliminary evidence of efficacy supports advancing to Phase II/III trials for pediatric brain tumors.
| Year | Citations | |
|---|---|---|
Page 1
Page 1